Kornimate/medical-research-clean huggingface dataset:
ga in newly diagnosed diffuse large b cell lymphoma

Conditions: Diffuse Large B Cell Lymphoma CD20 Positive

Summary: this study is designed to investigate: * the interest of a new monoclonal antibody (ga101)versus rituximab * the interest of pet to identify early responders patients will receive either rituximab (standard treatment), either ga101 (study treatment), according to the randomization arm. the monoclonal antibody will be associated to a chemotherapy: chop or acvbp according to site's choice.a pet scan will be done before inclusion, after 2 chemotherapy cycles, and after 4 chemotherapy cycles, to identify early patients responders, for who consolidation with asct is not required.


Eligibility criteria:
inclusion criteria: * histologically proven cd20+ diffuse large b cell lymphoma (who classification) * baseline pet scan available with at least one hypermetabolic lesion * aged ≥ 18 years and ≤ 60 years * eligible for autologous stem cell transplant * patient not previously treated * age adjusted international prognostic index (aa-ipi) equal to 1, 2 or 3 * life expectancy ≥ 3 months * negative hiv, hbv (anti-hbc negativity) and hcv serologies before inclusion * having signed a written informed consent * having ability and willingness to comply with study protocol procedures * men must agree to use a barrier method of contraception during the treatment period and until 3 months after the last dose of ga101 or rituximab, or acvbp14 or chop14 chemotherapy, whichever is longer * women of childbearing potential must agree to use an adequate method of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception during the treatment period and until 12 months after the last dose of ga101, rituximab, acvbp14, or chop14 chemotherapy, whichever is longer exclusion criteria: * any other histological type of lymphoma * any history of treated or non-treated indolent lymphoma. however, patients not previously diagnosed and having a diffuse large b-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included * central nervous system or meningeal involvement by lymphoma * contra-indication to any drug contained in the chemotherapy regimens * poor cardiac function (lvef \< 50%) on echocardiogram or muga scan * poor renal function (creatinine level \> 150\*mol/l or clearance \ 30µmol/l, transaminases \> 2.5 x maximum normal level) unless these abnormalities are related to the lymphoma * poor bone marrow reserve as defined by neutrophils \< 1.5 g/l or platelets \< 100 g/l, unless related to bone marrow infiltration * any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma * any serious active disease (according to the investigator's decision) * treatment with any investigational drug within 30 days before planned first cycle of chemotherapy * pregnant or lactating women * adult patient under tutelage * prior history of progressive multifocal leukoencephalopathy (pml)

Keywords: dlbcl aa-ipi > or equal to 1 diagnosis 18 to 60 years lymphoma
a clinical study to evaluate symbicort turbuhaler used 'as needed' in adults and adolescents with asthma.

Conditions: Asthma

Summary: the purpose of this study is to test if symbicort® (budesonide/formoterol) turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma. the efficacy of symbicort® 'as needed' will be compared with: 1) terbutaline turbuhaler® 'as needed' and with 2) pulmicort (budesonide) turbuhaler® twice daily plus terbutaline turbuhaler® 'as needed'.

a 52-week, double-blind, randomised, multi-centre, parallel-group, phase iii study in patients 12 years and older with asthma, evaluating the efficacy and safety of symbicort® (budesonide/formoterol) turbuhaler® 160/4.5 μg 'as needed' compared with terbutaline turbuhaler® 0.4 mg 'as needed' and with pulmicort® (budesonide) turbuhaler® 200 μg twice daily plus terbutaline turbuhaler® 0.4 mg 'as needed'

Eligibility criteria:
inclusion criteria 1. provision of informed consent prior to any study specific procedures. for patients under-age, signed informed consent from both the patient and the patient's parent/legal guardian is required 2. male or female, ≥12 years of age 3. documented diagnosis of asthma for at least 6 months prior to visit 1 4. patients who are in need of step 2 treatment according to global initiative for asthma guidelines 5. patients treated with 'as needed' inhaled short-acting bronchodilator(s) only should have pre-bronchodilator forced expiratory volume in one second (fev1) ≥ 60 % of predicted normal (pn) and post-bronchodilator fev1 ≥ 80 % pn 6. patients treated with low stable dose of inhaled corticosteroid or leukotriene antagonist in addition to 'as needed' use of inhaled short-acting bronchodilator(s) should have pre-bronchodilator fev1 ≥80 % pn 7. patients should have reversible airway obstruction 8. to be randomized patients must have used bricanyl turbuhaler 'as needed' on at least 3 separate days during the last week of the run in period. exclusion criteria 1. patient has a history of life-threatening asthma including intubation and intensive care unit admission 2. patient has had an asthma worsening requiring change in treatment other than inhaled short-acting bronchodilator(s) within 30 days prior to visit 1 or between visits 1 and 2; or a treatment other than bricanyl turbuhaler from visit 2 until randomization 3. patient has required treatment with oral, rectal or parenteral glucocorticosteroids (gcs) within 30 days and/or depot parenteral gcs within 12 weeks prior to visit 1 4. smoker (current or previous) with a smoking history of ≥ 10 pack years 5. pregnancy, breast-feeding or planned pregnancy during the study.
crp and lung ultrasound in respiratory evaluation

Conditions: Primary Health Care; Lower Respiratory Tract Infection

Summary: lower respiratory tract infections (lrtis) are one of the most common reasons for consultation in primary care centres. differentiating between viral and bacterial aetiologies can be challenging, leading to inappropriate antibiotic prescribing. lung ultrasound (lus), an imaging test that gained particular relevance since the beginning of the sars-cov-2 pandemic, offers several advantages over the classic chest x-ray in detecting and monitoring lrtis, especially when pleural involvement exists. this study aims to correlate lus findings with capillary blood c-reactive protein (crp) values in patients with lrtis, evaluating lus as a diagnostic tool and its impact on therapeutic decisions. the descriptive observational study, conducted from january 2024 to december 2026 in lleida, will include lrti patients attending primary care centres. by validating lus as a rapid and non-invasive diagnostic tool, unnecessary antibiotic prescriptions can be reduced, promoting lus as a complementary test in primary care consultations. this will facilitate appropriate diagnosis and treatment decisions for patients with lrtis, enhancing the overall management of respiratory infections.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * clinical suspicion of lrti defined as acute illness lasting less than 21 days, with cough as the main symptom, accompanied by at least one other lower respiratory symptom (such as sputum production, dyspnoea, difficult breathing, or chest pain) without any other explanation for the clinical picture. * ability to read, understand and willingness to give written consent to participate in the study. exclusion criteria: * patients who have been treated with antibiotics during the last 14 days up to inclusion. * patients with hemodynamic instability or that need emergency medical care due to the current clinical condition. * previous diagnosis of lung or pleural cancer. * thoracic surgery within the past 60 days. * lung interstitial diseases. * patients who refuse to participate in the study

Keywords: c-reactive protein lung ultrasonography lower respiratory tract infections
the effect of multi-target magnetic stimulation on freezing gait in pd

Conditions: Parkinson Disease

Summary: this study is a double-blinded randomized study examining the effectiveness of the multi-target magnetic stimulation treatment on freezing of gait (fog) phenomenon in patients with parkinson's disease. we hypothesize that treatment using magnetic stimulation on motor cortex combined with spinal cord will improve fog and gait symptoms in patients with parkinson's disease.

patients in the experimental group underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rtms) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord, whereas patients in the active comparator group underwent ten sessions of single active magnetic stimulation with low frequency rtms over the bilateral primary motor cortex of the lower leg. in addition, patients in the sham comparator group underwent 10 sessions of double sham rtms on motor cortex and spinal cord. assessments of fog, gait function, motor symptoms and excitability of primary motor cortex motor were performed three times: at baseline, one day post intervention, one month post intervention.

Eligibility criteria:
inclusion criteria: * 1.idiopathic parkinson's disease (pd), as diagnosed by a neurologist. * 2.item 3 of the freezing of gait questionnaire(fog-q) scored ≥1. * 3.age between 40 and 80 years old. * 4.mini-mental state examination score \>24. * 5.ability to walk 30 meters independently. * 6.stable medication. * 7.patients experienced fog in both medication "on" and "off" states. exclusion criteria: * 1.other neurological or psychiatric disorders. * 2.severe personality disorder.history of epilepsy, seizures, or convulsions. * 3.history of head injury or stroke. * 4.metal remains of the skull or inside the brain (outside the oral cavity). * 5.surgeries including metallic implants or known history of metal particles in the eye, pacemakers,hearing devices transplantation, or medical pumps. * 6.severe dyskinesia, termor, cognitive, visual or auditory impairment. * 7.patients who could not complete the follow-up.

Keywords: freezing of gait therapeutics rtms spinal cord stimulation
digital mindfulness meditation-enhanced cognitive behavioral therapy (cbt-mm) for binge eating disorder

Conditions: Binge Eating Disorder

Summary: the investigators will evaluate the acceptability and feasibility of a 18-week long digital mindfulness-based and cognitive behavioral therapy intervention for binge eating disorder. this study is a prospective single-arm trial during the intervention development phase. following this phase, after the intervention has been further developed, a subsequent study (with a different clinicaltrials.gov identification #) will utilize a randomized control trial design.

procedures include completing: (1) pre-intervention screening assessment; (2) an initial baseline visit; (3) 18-week web-based intervention; and (4) a post-intervention assessment (18-weeks after baseline).

Eligibility criteria:
inclusion criteria: * age 18 or older * meeting dsm-5 criteria for binge eating disorder (bed) * english-speaking exclusion criteria: * bmi \&lt; 18.5 * requiring immediate treatment for medical complications * current anorexia or bulimia nervosa or purging behaviors within the past year * already receiving treatment for an ed or participating in a weight loss program or psychotherapy focused on weight (psychotherapy for other conditions was allowed) * currently pregnant or breast-feeding * experiencing other severe psychopathology or medical illness that would limit the participants' ability to comply with the demands of the current study (e.g. active psychotic disorder, cancer)

Keywords: binge eating eating disorders obesity
a phase iii study of ivonescimab + chemo with/without ak117 vs chemo in metastatic pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of ivonescimab plus chemotherapy with or without ak117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. the study seeks to determine whether the addition of ivonescimab and/or ak117 improves clinical outcomes compared to standard chemotherapy alone. participants will be randomly assigned to receive either ivonescimab with/without ak117 or placebo, both in combination with chemotherapy.


Eligibility criteria:
inclusion criteria: 1. voluntarily sign a written informed consent form. 2. age at enrollment is ≥ 18 and ≤ 75 years, both males and females are eligible. 3. eastern cooperative oncology group (ecog) performance status of 0 or 1. 4. life expectancy of ≥ 3 months. 5. histologically or cytologically confirmed, unresectable metastatic pancreatic ductal adenocarcinoma (pdac). 6. no prior systemic anti-cancer treatment for metastatic pdac. 7. at least one measurable lesion per response evaluation criteria in solid tumors (recist) v1.1. 8. adequate organ function. exclusion criteria: 1. histologically or cytologically confirmed other types of pancreatic malignancies or mixed histology types. 2. presence of active central nerve system (cns) metastases. 3. known germline brca1/2 or palb2 mutations. 4. clinically significant or recurrent pleural effusion, pericardial effusion, or ascites requiring drainage. 5. history of other malignancies within the past 5 years. 6. history of significant bleeding tendencies or coagulopathy; clinically significant bleeding events within 1 month before the first dose. 7. previous anti-angiogenic therapy and immunotherapy. 8. active autoimmune disease requiring systemic treatment within the past 2 years. 9. pregnant or breastfeeding women. 10. concurrent participation in another clinical trial, unless it is an observational or non-interventional study or in the follow-up phase of an interventional study.
use of decision aids in clinical encounters

Conditions: Diabetes, Depression, Cardiovascular Disease,Hypercholesterolemia, Osteoporosis

Summary: the active strategy for dissemination and implementation of share evidence based medicine (ebm) will yield greater reach of clinicians, be adopted by the practices more readily, and a greater uptake of use amongst encounters will be seen. the institute for clinical systems improvement (icsi) is a nonprofit organization with expertise in large-scale practice improvement at the state and national level. largely funded by health organizations in minnesota, icsi has a sustainable model to translate evidence into practice, through clinical practice guidelines, shared decision making, and practice redesign. a partnership between these two organizations (icsi and mayo clinic) may lead to a sustainable and innovative approach to the dissemination of evidence-based health information at the point of care. the objective of the current study is therefore to leverage the expertise of these two organizations to compare the impact of an active to a passive dissemination and implementation strategy of the shareebm toolkit. the aim of the study is to disseminate evidence-based information through the use of decision aids during encounters. the overall purpose of the qualitative evaluation is to understand why decision aids were used more or less in certain practices and what factors contributed to or hindered this uptake.


Eligibility criteria:
inclusion criteria: * practices meeting the following criteria will be deemed eligible for the study if they have: 1. at least 2 primary care clinicians committed to participate in the study. clinicians are defined as any healthcare professional providing patient care (i.e., physicians, nurse practitioners, physician assistants, diabetes educators) 2. a designated site champion and support staff that can provide the support needed to conduct the study 3. an irb approval from their institution or are covered under mayo clinic irb 4. leadership is committed to this research and has endorsed the study * any clinician caring for patients with a chronic condition and who has opportunities to discuss medication management with their patients will be deemed eligible exclusion criteria: * major barriers to participating or to providing informed consent
high resolution hba-mri using deep learning reconstruction

Conditions: Liver Diseases; Magnetic Resonance Imaging; Deep Learning

Summary: this study aims to compare image qualities between conventionally reconstructed mri sequences and deep-learning reconstructed mri sequences from the same data in patients who undergo gd-eob-dtpa enhanced liver mri. the airtm deep learning sequence is applicable for various mri sequences including t2-weighted image (t2wi), t1-weighted image and diffusion-weighted image (dwi). we plan to perform intra-individual comparisons of the image qualities between two reconstructed image datasets.


Eligibility criteria:
inclusion criteria: * older than 20 years old * scheduled for gd-eob-dtpa enhanced liver mri at a 3t scanner (premier, ge healthcare) in our institution * signed informed consent exclusion criteria: * younger than 20 years old * any absolute/relative contrast indication of gd-eob-dtpa enhanced mri * history of transient dyspnea after gd-eob-dtpa administration
clinical efficacy and safety of t1225 versus tobramycin 0.3 % eye drops in the treatment of purulent bacterial conjunctivitis of children.

Conditions: Purulent Bacterial Conjunctivitis

Summary: efficacy/safety of t1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.


Eligibility criteria:
inclusion criteria: * age ≥ one day of life and ≤ 18 years * purulent bacterial conjunctivitis
a study of the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of pf-05180999 in healthy adults

Conditions: Migraine

Summary: pf-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of single doses of pf-05180999 in healthy adult subjects. histamine-induced wheals are biomarkers of vascular permeability.


Eligibility criteria:
inclusion criteria: * healthy male subjects between the ages of 18 and 55 years * no history of clinically-relevant atopic or dermatological disease * positive reaction to intradermal injection of histamine exclusion criteria: * subjects with screening laboratory test results that deviate from the upper and/or lower limits of the reference or acceptable range. the exception is that all liver function tests must not exceed the upper limit of normal. * subjects with evidence of, or history of, hepatic disorder, including acute or chronic hepatitis b or hepatitis c * intolerance to intradermal histamine injection. * subjects with dark skin (part b only).

Keywords: pf-05180999 safety tolerability pharmacokinetics histamine wheal flare migraine pde2
docetaxel, estramustine and short term androgen withdrawal for patients with a rising psa after local treatment

Conditions: Adenocarcinoma of the Prostate; Prostate Cancer

Summary: the purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. this study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate the effectiveness and side effects of the study drug

* patients will receive two medications; docetaxel and estramustine. estramustine will be taken orally three times daily for 5 days starting on day one. docetaxel will be given intravenously on day 2. these two drugs will be repeated every 3 weeks for a total of 4 cycles (12 weeks). * patients will also take dexamethasone for three days at the beginning of each cycle to help decrease the risk of side effects. * patients will also take coumadin every day for three months while on the chemotherapy to reduce the risk of blood clots. * after 12 weeks the chemotherapy phase will be completed and patient will start on the hormone therapy part of the treatment. three weeks after the last chemotherapy treatment, patients will start casodex orally once daily. * after taking casodex for 1 week, patients will then start on zoladex (an injection in the abdomen) every 3 months for a total of 5 injections. * during study treatment various blood tests will be performed to watch the disease. study treatment will stop after a total of 18 months (3 months chemotherapy and 15 months hormone therapy). a physical exam and blood tests will be performed every 3 months for 2 years, every 4 months for the third year, and then every 6 months after that.

Eligibility criteria:
inclusion criteria: * histologically documented adenocarcinoma of the prostate * previous treatment with either radical prostatectomy or radiation therapy * post prostatectomy: psa rising on at least two successive occasions at least two weeks apart * post radiation therapy alone: psa has to be rising as documented on two successive occasions at least two weeks apart and also have doubled from the nadir post treatment value * ecog performance status 0-1 * anc \> 1,500/mm3 * platelet counts \> 100,000/mm3 * sgot and/or sgpt may be up to 2.5 x uln exclusion criteria: * documented local recurrence of prostate cancer or documented metastatic disease * history of other malignancy within the last 5 years, other than curatively treated basal cell carcinoma of the skin * medical condition requiring the use of concommitant corticosteroids * active infection * significant cardiac disease, angina pectoris or myocardial infarction within six months * prior chemotherapy including estramustine, suramin * active thrombophlebitis or history of thromboembolic events in the six months preceding study treatment * clinically significant neuropathy * elevated bilirubin above uln

Keywords: prostate cancer psa level docetaxel estramustine hormone therapy androgen withdrawal
dementia early recognition and response in primary care

Conditions: Dementia

Summary: the purpose of this study is to develop and test an educational intervention for dementia in primary care, combining timely diagnosis, psychosocial support around the period of diagnosis and management concordant with guidelines.

dementia presents many challenges for primary care. early diagnosis is important as this allows those with dementia and their family care networks to engage with support services and plan for the future. these actions can relieve the significant psychological distress that people with dementia and close supporters may experience , and provide knowledge about the availability of medical and psycho-social support that can improved functioning and morale the main efforts to improve the identification and diagnosis of dementia should logically be targeted at primary care as this is the first point of contact for most individuals and their carers when faced with experiences of 'ill health'. there is, however, evidence that dementia remains under-detected and sub-optimally managed in general practice . an educational intervention that could enhance clinical practice, improving the skills of practitioners in the recognition of and response to dementia syndromes, could therefore be beneficial to people with dementia and their families, and potentially to health and social services.

Eligibility criteria:
inclusion criteria: * patients with memory or other cognitive impairments suggestive of dementia syndrome * those with a formal diagnosis of dementia, of any type. exclusion criteria: * patients and carers who are already involved in concurrent research * if the key professional feels that an approach to the person with dementia or their carer would be inappropriate, for example the dementia is very severe, or that an approach may increase distress * and any other important reason that the key professional may have for why the person with dementia or their carer should not be contacted.

Keywords: dementia primary care early diagnosis psychosocial interventions cholinesterase inhibitors